At Goldman Sachs' 46th Annual Global Healthcare Conference, Pfizer CEO Albert Bourla detailed the USD 1.2 billion upfront payment for 3SBio’s PD-1/VEGF bispecific SSGJ-707, calling it "a fabulous asset" with strong clinical data — though currently limited to China. Pfizer conducted weeks of on-site due diligence, visiting trial sites and interviewing investigators.
Bourla highlighted SSGJ-707’s strategic value, noting its
standalone potential and synergy with Pfizer’s ADC pipeline. The total deal
could reach USD 6 billion if successful. Pfizer’s 2024 BD budget is USD 10
billion to 15 billion, prioritising smaller deals.
Source: